Immunology Market By Product Type (Diagnostic Testing Equipment, Biomarkers, Biopharmaceuticals), By Application (Allergy and Hypersensitivity, Autoimmune Disease, Infectious Disease, HIV and AIDS, Others) By End User (Hospitals and Clinics, Pharmaceutical and Biotechnology Companies, Diagnostic Laboratories, Others) : Global Opportunity Analysis and Industry Forecast, 2024-2033
Immunology Market
The immunology market was valued at $110.1 billion in 2023 and is projected to reach $204.0 billion by 2033, growing at a CAGR of 6.3% from 2024 to 2033.
Immunology is a branch of science involved in studying the immune system of an organism. Immune system is the defense mechanism of a living body which fights against infections, foreign substances, and diseases. Immunology finds applications in diverse disciplines of medicine, including oncology, organ transplantation, rheumatology, bacteriology, virology, parasitology, dermatology, and psychiatry.
The immunology market is driven by rise in prevalence of immunological diseases and surge in awareness among individuals regarding the treatment of such diseases. In addition, governments across the globe have increased their expenditure in the field of science and medicine, thereby augmenting the growth of the immunology market. Boost in the trend of biosimilars and personalized medicine is currently presenting new prospects for the market. Moreover, personalized immunotherapy is projected to become mainstream in the future as a patient’s immune profile guides the treatment in this approach, hence elevating the effectiveness of the therapy and medications.
However, drug discovery is a lengthy process in immunology, which often requires 10-15 years of research in the laboratory, hence hampering the market growth. In addition, the stringent compliance requirements and the extended approval procedure of new drugs & treatments is a significant restraint for the market. For instance, the U.S. Food and Drug Administration has implemented a long series of regulations which is necessary to follow before releasing any drug in the market. This series involves preclinical testing, submission of investigational new drug application, three phases of clinical trials, submission of new drug application, and lastly post-market surveillance. Drug manufacturers are obliged to follow the sequence to ensure the efficacy and long-term effects of their medications.
Segment Review
The immunology market is segmented into product type, application, end user, and region. On the basis of product type, the market is divided into diagnostic testing equipment, biomarkers, and biopharmaceuticals. By application, it is classified into allergy & hypersensitivity, autoimmune disease, infectious disease, HIV & AIDS, and others. As per end user, it is categorized into hospitals & clinics, pharmaceutical & biotechnology companies, diagnostic laboratories, and others. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Key Findings
On the basis of product type, the biopharmaceuticals segment is expected to maintain its dominance during the forecast period.
By application, the autoimmune disease segment is projected to garner a high market share by 2033.
As per end user, the hospitals & clinics segment is anticipated to be the highest shareholder during the forecast period.
Region wise, North America is predicted to maintain its dominance by 2033.
Competition Analysis
The major players operating in the global immunology market include AbbVie Inc., Johnson & Johnson, Pfizer Inc., Novartis AG, Merck & Co., Inc., Bristol-Myers Squibb Company, Amgen Inc., Eli Lilly and Company, Gilead Sciences, Inc., and Sanofi. These players have adopted various key developmental strategies such as business expansion, new product launches, and partnerships to strengthen their foothold in the market.
Key Market Segments
By Product Type
Diagnostic Testing Equipment
Biomarkers
Biopharmaceuticals
By Application
Allergy and Hypersensitivity
Autoimmune Disease
Infectious Disease
HIV and AIDS
Others
By End User
Hospitals and Clinics
Pharmaceutical and Biotechnology Companies
Diagnostic Laboratories
Others
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
India
Australia
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
Key Market Players
AbbVie Inc.
Johnson & Johnson
Pfizer Inc.
Novartis AG
Merck & Co., Inc.
Bristol-Myers Squibb Company
Amgen Inc.
Eli Lilly and Company
Gilead Sciences, Inc.
Sanofi
- CHAPTER 1: INTRODUCTION
- 1.1. Report Description
- 1.2. Key Market Segments
- 1.3. Key Benefits
- 1.4. Research Methodology
- 1.4.1. Primary Research
- 1.4.2. Secondary Research
- 1.4.3. Analyst Tools and Models
- CHAPTER 2: EXECUTIVE SUMMARY
- 2.1. CXO Perspective
- CHAPTER 3: MARKET LANDSCAPE
- 3.1. Market Definition and Scope
- 3.2. Key Findings
- 3.2.1. Top Investment Pockets
- 3.2.2. Top Winning Strategies
- 3.3. Porter's Five Forces Analysis
- 3.3.1. Bargaining Power of Suppliers
- 3.3.2. Threat of New Entrants
- 3.3.3. Threat of Substitutes
- 3.3.4. Competitive Rivalry
- 3.3.5. Bargaining Power among Buyers
- 3.5. Market Dynamics
- 3.5.1. Drivers
- 3.5.2. Restraints
- 3.5.3. Opportunities
- CHAPTER 4: IMMUNOLOGY MARKET, BY PRODUCT TYPE
- 4.1. Market Overview
- 4.1.1 Market Size and Forecast, By Product Type
- 4.2. Diagnostic Testing Equipment
- 4.2.1. Key Market Trends, Growth Factors and Opportunities
- 4.2.2. Market Size and Forecast, By Region
- 4.2.3. Market Share Analysis, By Country
- 4.3. Biomarkers
- 4.3.1. Key Market Trends, Growth Factors and Opportunities
- 4.3.2. Market Size and Forecast, By Region
- 4.3.3. Market Share Analysis, By Country
- 4.4. Biopharmaceuticals
- 4.4.1. Key Market Trends, Growth Factors and Opportunities
- 4.4.2. Market Size and Forecast, By Region
- 4.4.3. Market Share Analysis, By Country
- CHAPTER 5: IMMUNOLOGY MARKET, BY APPLICATION
- 5.1. Market Overview
- 5.1.1 Market Size and Forecast, By Application
- 5.2. Allergy And Hypersensitivity
- 5.2.1. Key Market Trends, Growth Factors and Opportunities
- 5.2.2. Market Size and Forecast, By Region
- 5.2.3. Market Share Analysis, By Country
- 5.3. Autoimmune Disease
- 5.3.1. Key Market Trends, Growth Factors and Opportunities
- 5.3.2. Market Size and Forecast, By Region
- 5.3.3. Market Share Analysis, By Country
- 5.4. Infectious Disease
- 5.4.1. Key Market Trends, Growth Factors and Opportunities
- 5.4.2. Market Size and Forecast, By Region
- 5.4.3. Market Share Analysis, By Country
- 5.5. HIV And AIDS
- 5.5.1. Key Market Trends, Growth Factors and Opportunities
- 5.5.2. Market Size and Forecast, By Region
- 5.5.3. Market Share Analysis, By Country
- 5.6. Others
- 5.6.1. Key Market Trends, Growth Factors and Opportunities
- 5.6.2. Market Size and Forecast, By Region
- 5.6.3. Market Share Analysis, By Country
- CHAPTER 6: IMMUNOLOGY MARKET, BY END USER
- 6.1. Market Overview
- 6.1.1 Market Size and Forecast, By End User
- 6.2. Hospitals And Clinics
- 6.2.1. Key Market Trends, Growth Factors and Opportunities
- 6.2.2. Market Size and Forecast, By Region
- 6.2.3. Market Share Analysis, By Country
- 6.3. Pharmaceutical And Biotechnology Companies
- 6.3.1. Key Market Trends, Growth Factors and Opportunities
- 6.3.2. Market Size and Forecast, By Region
- 6.3.3. Market Share Analysis, By Country
- 6.4. Diagnostic Laboratories
- 6.4.1. Key Market Trends, Growth Factors and Opportunities
- 6.4.2. Market Size and Forecast, By Region
- 6.4.3. Market Share Analysis, By Country
- 6.5. Others
- 6.5.1. Key Market Trends, Growth Factors and Opportunities
- 6.5.2. Market Size and Forecast, By Region
- 6.5.3. Market Share Analysis, By Country
- CHAPTER 7: IMMUNOLOGY MARKET, BY REGION
- 7.1. Market Overview
- 7.1.1 Market Size and Forecast, By Region
- 7.2. North America
- 7.2.1. Key Market Trends and Opportunities
- 7.2.2. Market Size and Forecast, By Product Type
- 7.2.3. Market Size and Forecast, By Application
- 7.2.4. Market Size and Forecast, By End User
- 7.2.5. Market Size and Forecast, By Country
- 7.2.6. U.S. Immunology Market
- 7.2.6.1. Market Size and Forecast, By Product Type
- 7.2.6.2. Market Size and Forecast, By Application
- 7.2.6.3. Market Size and Forecast, By End User
- 7.2.7. Canada Immunology Market
- 7.2.7.1. Market Size and Forecast, By Product Type
- 7.2.7.2. Market Size and Forecast, By Application
- 7.2.7.3. Market Size and Forecast, By End User
- 7.2.8. Mexico Immunology Market
- 7.2.8.1. Market Size and Forecast, By Product Type
- 7.2.8.2. Market Size and Forecast, By Application
- 7.2.8.3. Market Size and Forecast, By End User
- 7.3. Europe
- 7.3.1. Key Market Trends and Opportunities
- 7.3.2. Market Size and Forecast, By Product Type
- 7.3.3. Market Size and Forecast, By Application
- 7.3.4. Market Size and Forecast, By End User
- 7.3.5. Market Size and Forecast, By Country
- 7.3.6. Germany Immunology Market
- 7.3.6.1. Market Size and Forecast, By Product Type
- 7.3.6.2. Market Size and Forecast, By Application
- 7.3.6.3. Market Size and Forecast, By End User
- 7.3.7. France Immunology Market
- 7.3.7.1. Market Size and Forecast, By Product Type
- 7.3.7.2. Market Size and Forecast, By Application
- 7.3.7.3. Market Size and Forecast, By End User
- 7.3.8. UK Immunology Market
- 7.3.8.1. Market Size and Forecast, By Product Type
- 7.3.8.2. Market Size and Forecast, By Application
- 7.3.8.3. Market Size and Forecast, By End User
- 7.3.9. Italy Immunology Market
- 7.3.9.1. Market Size and Forecast, By Product Type
- 7.3.9.2. Market Size and Forecast, By Application
- 7.3.9.3. Market Size and Forecast, By End User
- 7.3.10. Spain Immunology Market
- 7.3.10.1. Market Size and Forecast, By Product Type
- 7.3.10.2. Market Size and Forecast, By Application
- 7.3.10.3. Market Size and Forecast, By End User
- 7.3.11. Rest Of Europe Immunology Market
- 7.3.11.1. Market Size and Forecast, By Product Type
- 7.3.11.2. Market Size and Forecast, By Application
- 7.3.11.3. Market Size and Forecast, By End User
- 7.4. Asia-Pacific
- 7.4.1. Key Market Trends and Opportunities
- 7.4.2. Market Size and Forecast, By Product Type
- 7.4.3. Market Size and Forecast, By Application
- 7.4.4. Market Size and Forecast, By End User
- 7.4.5. Market Size and Forecast, By Country
- 7.4.6. Japan Immunology Market
- 7.4.6.1. Market Size and Forecast, By Product Type
- 7.4.6.2. Market Size and Forecast, By Application
- 7.4.6.3. Market Size and Forecast, By End User
- 7.4.7. China Immunology Market
- 7.4.7.1. Market Size and Forecast, By Product Type
- 7.4.7.2. Market Size and Forecast, By Application
- 7.4.7.3. Market Size and Forecast, By End User
- 7.4.8. India Immunology Market
- 7.4.8.1. Market Size and Forecast, By Product Type
- 7.4.8.2. Market Size and Forecast, By Application
- 7.4.8.3. Market Size and Forecast, By End User
- 7.4.9. Australia Immunology Market
- 7.4.9.1. Market Size and Forecast, By Product Type
- 7.4.9.2. Market Size and Forecast, By Application
- 7.4.9.3. Market Size and Forecast, By End User
- 7.4.10. South Korea Immunology Market
- 7.4.10.1. Market Size and Forecast, By Product Type
- 7.4.10.2. Market Size and Forecast, By Application
- 7.4.10.3. Market Size and Forecast, By End User
- 7.4.11. Rest of Asia-Pacific Immunology Market
- 7.4.11.1. Market Size and Forecast, By Product Type
- 7.4.11.2. Market Size and Forecast, By Application
- 7.4.11.3. Market Size and Forecast, By End User
- 7.5. LAMEA
- 7.5.1. Key Market Trends and Opportunities
- 7.5.2. Market Size and Forecast, By Product Type
- 7.5.3. Market Size and Forecast, By Application
- 7.5.4. Market Size and Forecast, By End User
- 7.5.5. Market Size and Forecast, By Country
- 7.5.6. Brazil Immunology Market
- 7.5.6.1. Market Size and Forecast, By Product Type
- 7.5.6.2. Market Size and Forecast, By Application
- 7.5.6.3. Market Size and Forecast, By End User
- 7.5.7. Saudi Arabia Immunology Market
- 7.5.7.1. Market Size and Forecast, By Product Type
- 7.5.7.2. Market Size and Forecast, By Application
- 7.5.7.3. Market Size and Forecast, By End User
- 7.5.8. South Africa Immunology Market
- 7.5.8.1. Market Size and Forecast, By Product Type
- 7.5.8.2. Market Size and Forecast, By Application
- 7.5.8.3. Market Size and Forecast, By End User
- 7.5.9. Rest of LAMEA Immunology Market
- 7.5.9.1. Market Size and Forecast, By Product Type
- 7.5.9.2. Market Size and Forecast, By Application
- 7.5.9.3. Market Size and Forecast, By End User
- CHAPTER 8: COMPETITIVE LANDSCAPE
- 8.1. Introduction
- 8.2. Top Winning Strategies
- 8.3. Product Mapping Of Top 10 Player
- 8.4. Competitive Dashboard
- 8.5. Competitive Heatmap
- 8.6. Top Player Positioning, 2023
- CHAPTER 9: COMPANY PROFILES
- 9.1. AbbVie Inc.
- 9.1.1. Company Overview
- 9.1.2. Key Executives
- 9.1.3. Company Snapshot
- 9.1.4. Operating Business Segments
- 9.1.5. Product Portfolio
- 9.1.6. Business Performance
- 9.1.7. Key Strategic Moves and Developments
- 9.2. Johnson And Johnson
- 9.2.1. Company Overview
- 9.2.2. Key Executives
- 9.2.3. Company Snapshot
- 9.2.4. Operating Business Segments
- 9.2.5. Product Portfolio
- 9.2.6. Business Performance
- 9.2.7. Key Strategic Moves and Developments
- 9.3. Pfizer Inc.
- 9.3.1. Company Overview
- 9.3.2. Key Executives
- 9.3.3. Company Snapshot
- 9.3.4. Operating Business Segments
- 9.3.5. Product Portfolio
- 9.3.6. Business Performance
- 9.3.7. Key Strategic Moves and Developments
- 9.4. Novartis AG
- 9.4.1. Company Overview
- 9.4.2. Key Executives
- 9.4.3. Company Snapshot
- 9.4.4. Operating Business Segments
- 9.4.5. Product Portfolio
- 9.4.6. Business Performance
- 9.4.7. Key Strategic Moves and Developments
- 9.5. Merck And Co., Inc.
- 9.5.1. Company Overview
- 9.5.2. Key Executives
- 9.5.3. Company Snapshot
- 9.5.4. Operating Business Segments
- 9.5.5. Product Portfolio
- 9.5.6. Business Performance
- 9.5.7. Key Strategic Moves and Developments
- 9.6. Bristol-Myers Squibb Company
- 9.6.1. Company Overview
- 9.6.2. Key Executives
- 9.6.3. Company Snapshot
- 9.6.4. Operating Business Segments
- 9.6.5. Product Portfolio
- 9.6.6. Business Performance
- 9.6.7. Key Strategic Moves and Developments
- 9.7. Amgen Inc.
- 9.7.1. Company Overview
- 9.7.2. Key Executives
- 9.7.3. Company Snapshot
- 9.7.4. Operating Business Segments
- 9.7.5. Product Portfolio
- 9.7.6. Business Performance
- 9.7.7. Key Strategic Moves and Developments
- 9.8. Eli Lilly And Company
- 9.8.1. Company Overview
- 9.8.2. Key Executives
- 9.8.3. Company Snapshot
- 9.8.4. Operating Business Segments
- 9.8.5. Product Portfolio
- 9.8.6. Business Performance
- 9.8.7. Key Strategic Moves and Developments
- 9.9. Gilead Sciences, Inc.
- 9.9.1. Company Overview
- 9.9.2. Key Executives
- 9.9.3. Company Snapshot
- 9.9.4. Operating Business Segments
- 9.9.5. Product Portfolio
- 9.9.6. Business Performance
- 9.9.7. Key Strategic Moves and Developments
- 9.10. Sanofi
- 9.10.1. Company Overview
- 9.10.2. Key Executives
- 9.10.3. Company Snapshot
- 9.10.4. Operating Business Segments
- 9.10.5. Product Portfolio
- 9.10.6. Business Performance
- 9.10.7. Key Strategic Moves and Developments
- TABLE 1. GLOBAL IMMUNOLOGY MARKET, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
- TABLE 2. IMMUNOLOGY MARKET FOR DIAGNOSTIC TESTING EQUIPMENT, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 3. IMMUNOLOGY MARKET FOR BIOMARKERS, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 4. IMMUNOLOGY MARKET FOR BIOPHARMACEUTICALS, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 5. GLOBAL IMMUNOLOGY MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 6. IMMUNOLOGY MARKET FOR ALLERGY AND HYPERSENSITIVITY, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 7. IMMUNOLOGY MARKET FOR AUTOIMMUNE DISEASE, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 8. IMMUNOLOGY MARKET FOR INFECTIOUS DISEASE, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 9. IMMUNOLOGY MARKET FOR HIV AND AIDS, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 10. IMMUNOLOGY MARKET FOR OTHERS, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 11. GLOBAL IMMUNOLOGY MARKET, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 12. IMMUNOLOGY MARKET FOR HOSPITALS AND CLINICS, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 13. IMMUNOLOGY MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 14. IMMUNOLOGY MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 15. IMMUNOLOGY MARKET FOR OTHERS, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 16. IMMUNOLOGY MARKET, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 17. NORTH AMERICA IMMUNOLOGY, BY COUNTRY, 2024 - 2033 ($BILLION)
- TABLE 18. NORTH AMERICA IMMUNOLOGY, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
- TABLE 19. NORTH AMERICA IMMUNOLOGY, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 20. NORTH AMERICA IMMUNOLOGY, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 21. U.S. IMMUNOLOGY, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
- TABLE 22. U.S. IMMUNOLOGY, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 23. U.S. IMMUNOLOGY, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 24. CANADA IMMUNOLOGY, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
- TABLE 25. CANADA IMMUNOLOGY, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 26. CANADA IMMUNOLOGY, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 27. MEXICO IMMUNOLOGY, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
- TABLE 28. MEXICO IMMUNOLOGY, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 29. MEXICO IMMUNOLOGY, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 30. EUROPE IMMUNOLOGY, BY COUNTRY, 2024 - 2033 ($BILLION)
- TABLE 31. EUROPE IMMUNOLOGY, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
- TABLE 32. EUROPE IMMUNOLOGY, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 33. EUROPE IMMUNOLOGY, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 34. GERMANY IMMUNOLOGY, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
- TABLE 35. GERMANY IMMUNOLOGY, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 36. GERMANY IMMUNOLOGY, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 37. FRANCE IMMUNOLOGY, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
- TABLE 38. FRANCE IMMUNOLOGY, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 39. FRANCE IMMUNOLOGY, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 40. UK IMMUNOLOGY, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
- TABLE 41. UK IMMUNOLOGY, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 42. UK IMMUNOLOGY, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 43. ITALY IMMUNOLOGY, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
- TABLE 44. ITALY IMMUNOLOGY, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 45. ITALY IMMUNOLOGY, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 46. SPAIN IMMUNOLOGY, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
- TABLE 47. SPAIN IMMUNOLOGY, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 48. SPAIN IMMUNOLOGY, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 49. REST OF EUROPE IMMUNOLOGY, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
- TABLE 50. REST OF EUROPE IMMUNOLOGY, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 51. REST OF EUROPE IMMUNOLOGY, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 52. ASIA-PACIFIC IMMUNOLOGY, BY COUNTRY, 2024 - 2033 ($BILLION)
- TABLE 53. ASIA-PACIFIC IMMUNOLOGY, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
- TABLE 54. ASIA-PACIFIC IMMUNOLOGY, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 55. ASIA-PACIFIC IMMUNOLOGY, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 56. JAPAN IMMUNOLOGY, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
- TABLE 57. JAPAN IMMUNOLOGY, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 58. JAPAN IMMUNOLOGY, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 59. CHINA IMMUNOLOGY, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
- TABLE 60. CHINA IMMUNOLOGY, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 61. CHINA IMMUNOLOGY, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 62. INDIA IMMUNOLOGY, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
- TABLE 63. INDIA IMMUNOLOGY, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 64. INDIA IMMUNOLOGY, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 65. AUSTRALIA IMMUNOLOGY, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
- TABLE 66. AUSTRALIA IMMUNOLOGY, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 67. AUSTRALIA IMMUNOLOGY, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 68. SOUTH KOREA IMMUNOLOGY, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
- TABLE 69. SOUTH KOREA IMMUNOLOGY, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 70. SOUTH KOREA IMMUNOLOGY, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 71. REST OF ASIA-PACIFIC IMMUNOLOGY, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
- TABLE 72. REST OF ASIA-PACIFIC IMMUNOLOGY, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 73. REST OF ASIA-PACIFIC IMMUNOLOGY, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 74. LAMEA IMMUNOLOGY, BY COUNTRY, 2024 - 2033 ($BILLION)
- TABLE 75. LAMEA IMMUNOLOGY, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
- TABLE 76. LAMEA IMMUNOLOGY, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 77. LAMEA IMMUNOLOGY, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 78. BRAZIL IMMUNOLOGY, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
- TABLE 79. BRAZIL IMMUNOLOGY, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 80. BRAZIL IMMUNOLOGY, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 81. SAUDI ARABIA IMMUNOLOGY, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
- TABLE 82. SAUDI ARABIA IMMUNOLOGY, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 83. SAUDI ARABIA IMMUNOLOGY, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 84. SOUTH AFRICA IMMUNOLOGY, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
- TABLE 85. SOUTH AFRICA IMMUNOLOGY, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 86. SOUTH AFRICA IMMUNOLOGY, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 87. REST OF LAMEA IMMUNOLOGY, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
- TABLE 88. REST OF LAMEA IMMUNOLOGY, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 89. REST OF LAMEA IMMUNOLOGY, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 90. ABBVIE INC.: KEY EXECUTIVES
- TABLE 91. ABBVIE INC.: COMPANY SNAPSHOT
- TABLE 92. ABBVIE INC.: OPERATING SEGMENTS
- TABLE 93. ABBVIE INC.: PRODUCT PORTFOLIO
- TABLE 94. ABBVIE INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 95. JOHNSON AND JOHNSON: KEY EXECUTIVES
- TABLE 96. JOHNSON AND JOHNSON: COMPANY SNAPSHOT
- TABLE 97. JOHNSON AND JOHNSON: OPERATING SEGMENTS
- TABLE 98. JOHNSON AND JOHNSON: PRODUCT PORTFOLIO
- TABLE 99. JOHNSON AND JOHNSON: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 100. PFIZER INC.: KEY EXECUTIVES
- TABLE 101. PFIZER INC.: COMPANY SNAPSHOT
- TABLE 102. PFIZER INC.: OPERATING SEGMENTS
- TABLE 103. PFIZER INC.: PRODUCT PORTFOLIO
- TABLE 104. PFIZER INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 105. NOVARTIS AG: KEY EXECUTIVES
- TABLE 106. NOVARTIS AG: COMPANY SNAPSHOT
- TABLE 107. NOVARTIS AG: OPERATING SEGMENTS
- TABLE 108. NOVARTIS AG: PRODUCT PORTFOLIO
- TABLE 109. NOVARTIS AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 110. MERCK AND CO., INC.: KEY EXECUTIVES
- TABLE 111. MERCK AND CO., INC.: COMPANY SNAPSHOT
- TABLE 112. MERCK AND CO., INC.: OPERATING SEGMENTS
- TABLE 113. MERCK AND CO., INC.: PRODUCT PORTFOLIO
- TABLE 114. MERCK AND CO., INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 115. BRISTOL-MYERS SQUIBB COMPANY: KEY EXECUTIVES
- TABLE 116. BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT
- TABLE 117. BRISTOL-MYERS SQUIBB COMPANY: OPERATING SEGMENTS
- TABLE 118. BRISTOL-MYERS SQUIBB COMPANY: PRODUCT PORTFOLIO
- TABLE 119. BRISTOL-MYERS SQUIBB COMPANY: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 120. AMGEN INC.: KEY EXECUTIVES
- TABLE 121. AMGEN INC.: COMPANY SNAPSHOT
- TABLE 122. AMGEN INC.: OPERATING SEGMENTS
- TABLE 123. AMGEN INC.: PRODUCT PORTFOLIO
- TABLE 124. AMGEN INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 125. ELI LILLY AND COMPANY : KEY EXECUTIVES
- TABLE 126. ELI LILLY AND COMPANY : COMPANY SNAPSHOT
- TABLE 127. ELI LILLY AND COMPANY : OPERATING SEGMENTS
- TABLE 128. ELI LILLY AND COMPANY : PRODUCT PORTFOLIO
- TABLE 129. ELI LILLY AND COMPANY : KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 130. GILEAD SCIENCES, INC.: KEY EXECUTIVES
- TABLE 131. GILEAD SCIENCES, INC.: COMPANY SNAPSHOT
- TABLE 132. GILEAD SCIENCES, INC.: OPERATING SEGMENTS
- TABLE 133. GILEAD SCIENCES, INC.: PRODUCT PORTFOLIO
- TABLE 134. GILEAD SCIENCES, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 135. SANOFI : KEY EXECUTIVES
- TABLE 136. SANOFI : COMPANY SNAPSHOT
- TABLE 137. SANOFI : OPERATING SEGMENTS
- TABLE 138. SANOFI : PRODUCT PORTFOLIO
- TABLE 139. SANOFI : KEY STRATEGIC MOVES AND DEVELOPMENTS
- FIGURE 1. GLOBAL IMMUNOLOGY MARKET SEGMENTATION
- FIGURE 2. GLOBAL IMMUNOLOGY MARKET
- FIGURE 3. SEGMENTATION IMMUNOLOGY MARKET
- FIGURE 4. TOP INVESTMENT POCKET IN IMMUNOLOGY MARKET
- FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
- FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
- FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
- FIGURE 8. LOW THREAT OF SUBSTITUTION
- FIGURE 9. HIGH COMPETITIVE RIVALRY
- FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALIMMUNOLOGY MARKET
- FIGURE 11. GLOBAL IMMUNOLOGY MARKET SEGMENTATION, BY PRODUCT TYPE
- FIGURE 12. IMMUNOLOGY MARKET FOR DIAGNOSTIC TESTING EQUIPMENT, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 13. IMMUNOLOGY MARKET FOR BIOMARKERS, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 14. IMMUNOLOGY MARKET FOR BIOPHARMACEUTICALS, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 15. GLOBAL IMMUNOLOGY MARKET SEGMENTATION, BY APPLICATION
- FIGURE 16. IMMUNOLOGY MARKET FOR ALLERGY AND HYPERSENSITIVITY, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 17. IMMUNOLOGY MARKET FOR AUTOIMMUNE DISEASE, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 18. IMMUNOLOGY MARKET FOR INFECTIOUS DISEASE, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 19. IMMUNOLOGY MARKET FOR HIV AND AIDS, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 20. IMMUNOLOGY MARKET FOR OTHERS, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 21. GLOBAL IMMUNOLOGY MARKET SEGMENTATION, BY END USER
- FIGURE 22. IMMUNOLOGY MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 23. IMMUNOLOGY MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 24. IMMUNOLOGY MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 25. IMMUNOLOGY MARKET FOR OTHERS, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 26. TOP WINNING STRATEGIES, BY YEAR, 2021-2023*
- FIGURE 27. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2021-2023*
- FIGURE 28. TOP WINNING STRATEGIES, BY COMPANY, 2021-2023*
- FIGURE 29. PRODUCT MAPPING OF TOP 10 PLAYERS
- FIGURE 30. COMPETITIVE DASHBOARD
- FIGURE 31. COMPETITIVE HEATMAP: IMMUNOLOGY MARKET
- FIGURE 32. TOP PLAYER POSITIONING, 2023
- FIGURE 33. ABBVIE INC.: NET SALES, 2021-2023 ($BILLION)
- FIGURE 34. ABBVIE INC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 35. ABBVIE INC.: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 36. JOHNSON AND JOHNSON: NET SALES, 2021-2023 ($BILLION)
- FIGURE 37. JOHNSON AND JOHNSON: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 38. JOHNSON AND JOHNSON: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 39. PFIZER INC.: NET SALES, 2021-2023 ($BILLION)
- FIGURE 40. PFIZER INC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 41. PFIZER INC.: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 42. NOVARTIS AG: NET SALES, 2021-2023 ($BILLION)
- FIGURE 43. NOVARTIS AG: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 44. NOVARTIS AG: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 45. MERCK AND CO., INC.: NET SALES, 2021-2023 ($BILLION)
- FIGURE 46. MERCK AND CO., INC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 47. MERCK AND CO., INC.: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 48. BRISTOL-MYERS SQUIBB COMPANY: NET SALES, 2021-2023 ($BILLION)
- FIGURE 49. BRISTOL-MYERS SQUIBB COMPANY: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 50. BRISTOL-MYERS SQUIBB COMPANY: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 51. AMGEN INC.: NET SALES, 2021-2023 ($BILLION)
- FIGURE 52. AMGEN INC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 53. AMGEN INC.: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 54. ELI LILLY AND COMPANY : NET SALES, 2021-2023 ($BILLION)
- FIGURE 55. ELI LILLY AND COMPANY : REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 56. ELI LILLY AND COMPANY : REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 57. GILEAD SCIENCES, INC.: NET SALES, 2021-2023 ($BILLION)
- FIGURE 58. GILEAD SCIENCES, INC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 59. GILEAD SCIENCES, INC.: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 60. SANOFI : NET SALES, 2021-2023 ($BILLION)
- FIGURE 61. SANOFI : REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 62. SANOFI : REVENUE SHARE, BY REGION, 2023 (%)
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook